A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

Background: Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement...

Full description

Bibliographic Details
Main Authors:	Jinfang Song, Xia Li, Jiang Ni
Format:	Article
Language:	English
Published:	Karger Publishers 2023-09-01
Series:	Kidney & Blood Pressure Research
Subjects:	sglt2 inhibitor diabetic kidney disease non-diabetic kidney disease chronic kidney disease
Online Access:	https://beta.karger.com/Article/FullText/534174

Similar Items

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
by: Anoushka Krishnan, et al.
Published: (2023-04-01)

Best Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
by: Jay H. Shubrook, et al.
Published: (2023-10-01)

A prospective study to evaluate the effects of sodium-glucose cotransporter 2 inhibitors in type 2 diabetic patients with chronic kidney disease
by: Neil Saldanha, et al.
Published: (2022-01-01)

Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
by: Xiutian Chen, et al.
Published: (2022-12-01)

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
by: Giovanna Castoldi, et al.
Published: (2024-03-01)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
by: Daniel H. Van Raalte, et al.
Published: (2022-05-01)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
by: Roko Skrabic, et al.
Published: (2022-10-01)

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
by: Michał Szczepański, et al.
Published: (2024-12-01)

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
by: Minara S. Shamkhalova, et al.
Published: (2022-11-01)

Effects of sodium-glucose cotransporter-2 inhibitors on chronic kidney disease progression: a multi-state survival model
by: Amarit Tansawet, et al.
Published: (2024-11-01)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
by: Xiaoya Sun, et al.
Published: (2022-12-01)

Treatment and practical considerations of diabetic kidney disease
by: Yara Bilen, et al.
Published: (2023-12-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

Narrative review investigating the nephroprotective mechanisms of sodium glucose cotransporter type 2 inhibitors in diabetic and nondiabetic patients with chronic kidney disease
by: Emma S. Speedtsberg, et al.
Published: (2023-12-01)

SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations
by: Erietta Polychronopoulou, et al.
Published: (2024-04-01)

The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study
by: Timna Agur, et al.
Published: (2025-02-01)

Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
by: Supattra Hunsuwan, et al.
Published: (2025-01-01)

Short‐term outcomes after sodium‐glucose cotransporter‐2 inhibitor initiation in a cohort of heart failure patients
by: Bryan O. Pérez Martínez, et al.
Published: (2023-10-01)

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
by: Colbert GB, et al.
Published: (2023-02-01)

Real-world national trends and socio-economic factors preference of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in China
by: Cao Li, et al.
Published: (2022-10-01)

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
by: Marina V. Leonova
Published: (2024-05-01)

Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
by: Irene Capelli, et al.
Published: (2023-04-01)

Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis
by: Yi Liu, et al.
Published: (2023-12-01)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
by: Shen L, et al.
Published: (2021-04-01)

Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular Filtration Rate
by: Kayla Chonko, et al.
Published: (2023-06-01)

Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review
by: Robert J. Mentz, et al.
Published: (2023-11-01)

Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in Chronic Kidney Disease
by: Mohamad Hanouneh, et al.
Published: (2024-06-01)

Inhibition of sodium‐glucose cotransporter 2 ameliorates renal injury in a novel medaka model of nonalcoholic steatohepatitis‐related kidney disease
by: Takuro Nagoya, et al.
Published: (2019-12-01)

Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study
by: Ngai Mui Ng, et al.
Published: (2022-12-01)

Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience
by: Mohammed H Tawhari, et al.
Published: (2023-01-01)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022-07-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
by: John S. Clemmer, et al.
Published: (2023-11-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease
by: Riccardo Nevola, et al.
Published: (2022-03-01)

Role of Metformin in Preventing New-Onset Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus
by: Yu-Ling Lin, et al.
Published: (2025-01-01)

Treatment of diabetes mellitus in patients with chronic kidney disease - a review of the latest research.
by: Natalia Wierzbowska, et al.
Published: (2022-03-01)

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
by: Zhi-Cheng Dai, et al.
Published: (2023-09-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors in the Management of Chronic Kidney Disease: A Middle East and Africa Perspective
by: Elkeraie AF, et al.
Published: (2024-01-01)

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
by: Bo Xu, et al.
Published: (2022-05-01)